Like what you're reading? Please Support Us!

New Study Shows One Company’s Vaccine Has No Problem Protecting Against Delta

The following article, New Study Shows One Company’s Vaccine Has No Problem Protecting Against Delta, was first published on Flag And Cross.

We were so close.  Normalcy was just a few weeks away it seemed, as we slogged through the last bits of resistance of the coronavirus pandemic.

America had just begun to get back into the swing of things of late, returning not only to restaurants and bars, but to music venues and ballparks too.  But then came the delta variant, spreading far more rapidly than the original COVID-19 strain, and picking off a great number of folks – some of whom were fully vaccinated.

A new study now shows that at least one of the three major vaccines is highly effective against delta.

Moderna’s COVID-19 vaccine resulted in antibody activity against variants, including the highly transmissible delta variant, six months after the second dose, a study found. However, antibody levels waned over time, and researchers said the results inform the potential need for a booster shot.

“Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6-months after the primary series of the mRNA-1273 vaccine,” study authors wrote.

The study, led by the National Institutes of Health, was published in the Science journal late Thursday, drawing from an analysis of blood samples from 24 participants across several age groups (18-55, 55-70, and 71+), finding that 96% of samples neutralized the delta variant. However, neutralizing activity was lowest against the B.1.351 variant first detected in South Africa, with 54% of samples neutralizing the variant, or a 1.5-fold reduction and 3-fold reduction, respectively.

The company was glad to hear it.

“We are pleased with these new data showing that people vaccinated with two doses of the Moderna COVID-19 vaccine maintained antibodies through six months, including against variants of concern such as the Delta variant,” Stéphane Bancel, CEO of Moderna, said in a news release. “These data support the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months. We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses.”

Earlier in the week, results of a study testing the efficacy of the Pfizer vaccine against the delta variant came back with much different results, as that brand of inoculation appeared to be only 42% effective.

Continue reading: New Study Shows One Company’s Vaccine Has No Problem Protecting Against Delta ...

Leave a Reply

Notify of

Like what you're reading? Please Support Us!